Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | COMT | P21964 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | METAP2 | P50579 | 1/20 | 0.63 |
| ▸ | METAP1 | P53582 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthroline SCHEMBL28178589 | 0.85 | MMP2 (0.73) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL1286608 | 0.83 | MMP2 (0.63) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL9379959 | 0.81 | MMP2 (0.61) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL623096 | 0.79 | LMNA (0.63) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL10087891 | 0.79 | HSP90AA1 (0.58) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL114706 | 0.79 | KDM4E (0.58) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL5540587 | 0.79 | MMP2 (0.59) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL20480582 | 0.79 | MMP2 (0.59) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL112625 | 0.79 | MMP2 (0.58) | MMP2TSHRCHRM1COMTADRA1A | |
| SCHEMBL113907 | 0.79 | LMNA (0.58) | MMP2TSHRCHRM1COMTADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-2038280-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-6635656-B1 | Isolated from sponge haliclona tulearensis; antitumor agents | PHARMA MAR, S.A. (ES) | 2003-10-21 | — | — | US | disclosed |
| EP-1119565-A1 | CYTOTOXIC ALKALOIDS (HALITULIN) | PHARMA MAR, S.A. (ES) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020411-A1 | CYTOTOXIC ALKALOIDS (HALITULIN) | PHARMA MAR, S.A. (ES) | 2000-04-13 | — | — | WO | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | MMP2 4465/4885TSHR 623/4885CHRM1 180/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | MMP2 2102/4885TSHR 4812/4885CHRM1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.